Core Insights - Adtalem Global Education reported quarterly earnings of $2.43 per share, exceeding the Zacks Consensus Estimate of $2.19 per share, and showing an increase from $1.81 per share a year ago, resulting in an earnings surprise of +11.21% [1] - The company achieved revenues of $503.39 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.17% and up from $447.73 million year-over-year [2] - Adtalem's stock has increased approximately 11.4% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.09 on revenues of $488.26 million, while for the current fiscal year, the estimate is $7.85 on revenues of $1.92 billion [7] - The estimate revisions trend for Adtalem was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Schools industry, to which Adtalem belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Nerdy Inc., is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of +33.3%, with revenues projected at $45.71 million, down 4.8% from the previous year [9]

Financial Data and Key Metrics Changes - Total revenue increased by 12.4% to $503.4 million, driven by all three segments [17] - Adjusted EBITDA grew to $154.9 million, up 23.9% compared to the prior year [18] - Adjusted earnings per share rose to $2.43, a 34.3% increase year-over-year [19] - Operating cash flow generation for the trailing twelve months was $428 million, up $146 million from the previous year [20] Business Line Data and Key Metrics Changes - Chamberlain reported revenue of $183.8 million, a 1.6% increase, but total student enrollment declined by 1% [22] - Walden's revenue increased by 27% to $217.6 million, with total student enrollment up 13% [23] - Medical and Veterinary segment revenue was $102 million, a 6.9% increase, with adjusted EBITDA rising by 17.6% [25] Market Data and Key Metrics Changes - Total enrollment grew over 6% to 97,000 students, marking the tenth consecutive quarter of enrollment growth [4][7] - Chamberlain's pre-licensure BSN programs have seen growth for 14 consecutive quarters, while post-licensure programs faced declines [22] - Walden's growth was particularly strong in behavioral sciences and nursing programs [32] Company Strategy and Development Direction - The company is focused on addressing the healthcare workforce crisis by expanding capacity and creating new revenue streams [7] - A disciplined, returns-focused approach to capital allocation is being maintained, with $165 million deployed for share repurchases [4] - The upcoming Investor Day will outline a multi-year growth framework [7][47] Management's Comments on Operating Environment and Future Outlook - The healthcare workforce crisis is intensifying, with significant gaps expected to deepen, particularly in rural and underserved areas [6][7] - Management remains confident in achieving full-year revenue guidance of 6%-8.5% growth and has raised adjusted EPS guidance to 17%-20% growth [4][27] - The company expects application growth at Chamberlain to translate into future enrollment growth [27] Other Important Information - The company has approximately $728 million remaining on its current share repurchase authorization [4] - Adjusted EBITDA margin expanded by 290 basis points to 30.8% [18] - The one-week academic calendar shift contributed an additional $18 million in revenue for Walden in Q2 [17][26] Q&A Session Summary Question: Can you provide insights on Walden's growth and market share? - Management noted that growth is consistent across programs, particularly in behavioral sciences and nursing, indicating potential market share gains [32] Question: What is the status of the partnership with Sallie Mae regarding loan caps? - Management confirmed they are working on definitive documentation for the partnership and are optimistic about its implications for the portfolio [33] Question: Can you elaborate on Chamberlain's enrollment trends and lead times? - Management acknowledged recent improvements in application volumes and expressed confidence in returning to positive enrollment growth by the fall cycle [39][40] Question: What factors could lead to exceeding the high end of revenue guidance? - Management indicated that quicker recovery at Chamberlain and acceleration in the Med Vet segment could contribute to exceeding guidance [42]

Financial Data and Key Metrics Changes - Revenue in Q2 increased by 12.4% to $503.4 million, driven by all three segments, with Walden contributing significantly due to a one-week academic calendar shift [17][26] - Adjusted EBITDA grew to $154.9 million, up 23.9% year-over-year, with an adjusted EBITDA margin of 30.8%, expanding 290 basis points from last year [18][25] - Adjusted net income for the quarter was $87.9 million, a 26.7% increase compared to last year, with adjusted earnings per share rising to $2.43, a 34.3% increase [19][20] Business Line Data and Key Metrics Changes - Chamberlain reported revenue of $183.8 million, a 1.6% increase, but total student enrollment declined by 1% [22] - Walden's revenue reached $217.6 million, a 27% increase, with total student enrollment up 13% [23] - The Medical and Veterinary segment generated $102 million in revenue, a 6.9% increase, with adjusted EBITDA increasing by 17.6% [24][25] Market Data and Key Metrics Changes - Total enrollment across the company grew over 6% to 97,000 students, with Walden achieving record total enrollments of 52,400 students [7][11] - Chamberlain's pre-licensure BSN programs have grown for 14 consecutive quarters, while post-licensure programs faced declines [22][10] Company Strategy and Development Direction - The company is focused on addressing the healthcare workforce crisis by expanding capacity and creating new revenue streams [6][7] - A disciplined, returns-focused approach to capital allocation is being maintained, with $165 million deployed to share repurchases [4][20] - The upcoming Investor Day will outline a multi-year growth framework and capacity expansion plans [7][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue guidance of 6%-8.5% growth and raised adjusted EPS guidance to 17%-20% growth [4][27] - The healthcare workforce crisis is intensifying, creating opportunities for the company to expand its role in healthcare education [6][7] - Management noted that application volumes for nursing programs are up, indicating potential future enrollment growth [10][39] Other Important Information - The company repurchased 1.7 million shares at an average price of $95, completing a prior $150 million authorization and announcing a new $750 million authorization [20] - The trailing twelve months operating cash flow generation reached $428 million, up $146 million year-over-year [20] Q&A Session Summary Question: Update on Walden's growth and market share - Management noted balanced growth across programs, particularly in behavioral sciences and nursing, indicating potential market share gains [32] Question: Regulatory changes and partnership with Sallie Mae - Management confirmed ongoing work with Sallie Mae on documentation for a partnership to provide loan dollars, particularly for the medical and veterinary segment [33] Question: Chamberlain's enrollment and marketing effectiveness - Management discussed improvements in application volumes and marketing effectiveness, expressing confidence in a positive enrollment trajectory for the fall cycle [39][40]

Financial Data and Key Metrics Changes - Total revenue increased by 12.4% to $503.4 million, driven by all three segments [15] - Adjusted EBITDA grew to $154.9 million, up 23.9% year-over-year, with an adjusted EBITDA margin of 30.8% [16] - Adjusted net income for the quarter was $87.9 million, a 26.7% increase compared to last year, with adjusted earnings per share rising to $2.43, a 34.3% increase [17] Business Line Data and Key Metrics Changes - Chamberlain reported revenue of $183.8 million, a 1.6% increase, but total student enrollment declined by 1% [19] - Walden's revenue reached $217.6 million, a 27% increase, with total student enrollment up 13% [20][21] - The Medical and Veterinary segment generated $102 million in revenue, a 6.9% increase, with adjusted EBITDA rising by 17.6% [22][23] Market Data and Key Metrics Changes - Total enrollment across the company grew over 6% to 97,000 students [6] - Chamberlain's pre-licensure BSN programs have seen growth for 14 consecutive quarters, while post-licensure programs faced declines [19] - Walden's growth was particularly strong in behavioral sciences and nursing programs [29] Company Strategy and Development Direction - The company is focused on addressing the healthcare workforce crisis by expanding capacity and creating new revenue streams [6] - A multi-year growth framework will be presented at the upcoming Investor Day, emphasizing sustainable earnings growth [6][43] - The company aims to maintain a disciplined, returns-focused approach to capital allocation, having repurchased $165 million in shares [4] Management's Comments on Operating Environment and Future Outlook - The healthcare workforce crisis is intensifying, with significant gaps expected in rural and underserved urban areas [6] - Management remains confident in achieving full-year revenue guidance of 6%-8.5% growth and has raised adjusted EPS guidance to 17%-20% growth [4][25] - The company anticipates that application growth at Chamberlain will translate into future enrollment growth [25] Other Important Information - The company has approximately $728 million remaining on its current share repurchase authorization [4] - A one-week academic calendar shift contributed an additional $18 million in revenue for Walden in Q2 [15][24] Q&A Session Summary Question: Can you elaborate on Walden's growth and market share? - Management noted that Walden's growth is consistent across programs, particularly in behavioral sciences and nursing, indicating a balanced growth across the program mix [29] Question: What is the status of the partnership with Sallie Mae regarding loan caps? - Management confirmed they are working on definitive documentation for the partnership and are excited about its potential impact on the portfolio [30] Question: What are the expectations for Chamberlain's enrollment and lead time? - Management expressed confidence in the trajectory of recovery for Chamberlain, with positive early signals in application volumes and a focus on the fall enrollment cycle [36]

Second Quarter 2026 Earnings January 28, 2026 A D T A L E M : T h i r d Q u a r t e r 2 0 2 5 R e s u l t s / 1 Safe Harbor Safe Harbor CAUTIONARY DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this presentation are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any his ...

Revenue Growth - Adtalem's revenue increased by 12.4%, or $55.7 million, to $503.4 million in Q2 FY 2026 compared to the prior year period, driven by growth across all segments [138]. - Walden's revenue surged by 27.0%, or $46.3 million, to $217.6 million in Q2 FY 2026, driven by increased enrollment and higher tuition rates [147]. - Chamberlain's revenue increased by 1.6%, or $2.8 million, to $183.8 million in Q2 FY 2026, supported by higher tuition rates despite a decline in post-licensure nursing program enrollment [145]. - Medical and Veterinary revenue grew by 6.9%, or $6.6 million, to $102.0 million in Q2 FY 2026, attributed to higher enrollment and tuition rates [149]. Income and Earnings - Net income rose by 0.7%, or $0.5 million, to $76.4 million in Q2 FY 2026, primarily due to increased revenue and decreased interest expense [138]. - Adjusted net income increased by 26.7%, or $18.5 million, to $87.9 million in Q2 FY 2026, reflecting strong revenue growth and lower interest expenses [138]. - Consolidated operating income increased 7.0%, or $7.2 million, to $111.1 million in the second quarter of fiscal year 2026 compared to the prior year [158]. - Adjusted net income for the six months ended December 31, 2025, was $152.8 million, compared to $119.9 million in the prior year [213]. Enrollment Trends - Total student enrollment at Chamberlain decreased by 1.0% for the November 2025 session compared to the same session last year, while Walden's enrollment increased by 13.0% as of December 31, 2025 [138]. Tuition Rates - Tuition rates for Chamberlain programs increased by approximately 4.6% from the prior year, while Walden's rates increased by about 2.0% [146][148]. - Tuition rates for RUSM's medical program increased by 4.5% and for RUSVM's veterinary program by 3.0% effective September 2025 [153]. Expenses and Cost Management - Cost of educational services increased 10.1%, or $18.8 million, to $205.4 million in the second quarter of fiscal year 2026 compared to the prior year [151]. - As a percentage of revenue, cost of educational services was 40.8% in the second quarter of fiscal year 2026, down from 41.7% in the prior year period, indicating improved cost efficiencies [152]. - Student services and administrative expense increased 16.5%, or $25.9 million, to $182.8 million in the second quarter of fiscal year 2026 compared to the prior year [154]. Operating Income - Operating income for Chamberlain decreased 24.2%, or $10.2 million, to $32.0 million in the second quarter of fiscal year 2026 compared to the prior year [158]. - Operating income for Walden increased 53.8%, or $26.3 million, to $75.2 million in the second quarter of fiscal year 2026 compared to the prior year [158]. - Walden's segment adjusted operating income increased by 70.0%, or $32.3 million, to $78.5 million in Q2 FY 2026, and increased by 51.5%, or $45.7 million, to $134.5 million in the first six months compared to the prior year [162]. Share Repurchase and Financing - Adtalem repurchased 1,727,565 shares at an average cost of $95.45 per share during Q2 FY 2026, with future repurchases dependent on market conditions [138]. - Adtalem authorized a share repurchase program allowing for the repurchase of up to $750.0 million of common stock through December 15, 2028, with $727.5 million remaining as of December 31, 2025 [194][195]. - Net cash used in financing activities was $267.2 million for the six months ended December 31, 2025, driven by share repurchases of $172.4 million [193]. Cash Flow and Liquidity - Adtalem's net cash provided by operating activities increased by $94.2 million to $160.1 million for the six months ended December 31, 2025, compared to $66.0 million in the prior year period [191]. - Cash collections from students rose by $81.0 million, contributing to the overall increase in operating cash flow [191]. - As of December 31, 2025, Adtalem's consolidated cash and cash equivalents totaled $56.3 million, down from $199.6 million as of June 30, 2025 [190]. Regulatory and Compliance - The One Big Beautiful Bill Act (OBBBA) may significantly impact federal student aid availability, which could affect Adtalem's business operations [140]. - Adtalem's composite score declined to 0.2 as of September 25, 2023, impacting its eligibility for Title IV programs, but management does not expect material adverse effects on operations [176]. - New Gainful Employment rules effective July 1, 2024, require programs to meet specific debt-to-earnings and earnings premium tests to maintain Title IV eligibility [183]. - Adtalem's institutions are subject to heightened cash monitoring and additional reporting requirements due to provisional certifications stemming from the decline in the composite score [181]. Interest and Other Income - Interest expense decreased to $10.9 million in Q2 FY 2026 and $22.0 million in the first six months, down from $13.9 million and $28.4 million in the prior year periods [164]. - Other income, net was $1.7 million in Q2 FY 2026 and $4.2 million in the first six months, compared to $2.2 million and $4.9 million in the prior year periods [165]. Adjusted Earnings and EBITDA - Adjusted earnings per share for the six months ended December 31, 2025, was $4.17, up from $3.09 in the prior year [214]. - Adjusted EBITDA for Adtalem Global Education increased by 23.9% to $154,903,000 for the three months ended December 31, 2025, compared to $125,012,000 in the same period of 2024 [216]. - Adjusted EBITDA margin for Adtalem Global Education improved to 30.8% for the three months ended December 31, 2025, up from 27.9% in the same period of 2024 [216].

Exhibit 99.1 Investor Contact: Jay Spitzer Investor.Relations@Adtalem.com +1 312-906-6600 Media Contact: Maureen Bender AdtalemMedia@Adtalem.com +1 313-319-4732 ADTALEM GLOBAL EDUCATION SECOND QUARTER FISCAL YEAR 2026 RESULTS; RAISES FISCAL YEAR 2026 ADJUSTED EARNINGS PER SHARE GUIDANCE Total enrollment up 6.3% YoY Revenue up 12.4% YoY Diluted earnings per share $2.11; Adjusted EPS $2.43, growth of 34.3% YoY SECOND QUARTER HIGHLIGHTS CAPITAL ALLOCATION FISCAL YEAR 2026 GUIDANCE INVESTOR DAY 2026 ● Company t ...

Adtalem Global Education Second Quarter Fiscal Year 2026 Results; Raises Fiscal Year 2026 Adjusted Earnings Per Share GuidanceJan 28, 2026 4:15 PM Eastern Standard Time# Adtalem Global Education Second Quarter Fiscal Year 2026 Results; Raises Fiscal Year 2026 Adjusted Earnings Per Share GuidanceShare---Total enrollment up 6.3% YoYRevenue up 12.4% YoYDiluted earnings per share $2.11; Adjusted EPS $2.43, growth of 34.3% YoYSecond quarter highlights- Sustaining momentum, GAAP net income $76.4 million; adjusted ...

Core Insights - Adtalem Global Education Inc. has been named "Stock to Study" by BetterInvesting Magazine for March 2026, indicating potential interest from investors regarding its stock valuation [1] - A comprehensive report on Adtalem's financial metrics, including sales, earnings, and return on equity, will be available in the upcoming issue of BetterInvesting Magazine [2] - The same issue will also feature a fundamental review of Trex Company, which is considered undervalued by the Editorial Advisory and Securities Review Committee [3] Company Overview - Adtalem Global Education Inc. is under scrutiny for its stock valuation, prompting further analysis by BetterInvesting Magazine [1] - The National Association of Investors Corp. provides detailed financial data for Adtalem, allowing investors to assess its performance metrics [2] - The Editorial Advisory and Securities Review Committee of BetterInvesting includes several CFA members, indicating a professional approach to stock evaluation [3]

Core Insights - The U.S. education market is transitioning from traditional methods to digital and career-focused programs, driven by student demand and government initiatives [2][11] - The Zacks Schools industry shows resilience, with median share prices above the S&P 500 composite, indicating promising mid to long-term prospects despite current stock performance [3] - Five education stocks are identified with expected earnings growth of over 10% year-over-year by 2026, including Chegg, Adtalem Global Education, Grand Canyon Education, Nerdy, and Legacy Education [4] Market Trends - The shift towards hybrid and AI-based learning models is gaining traction, with education companies adapting to meet the demand for flexible learning formats [5][8] - Companies like Chegg and Nerdy are benefiting from the rise of online and hybrid learning, leveraging AI-enhanced tools and subscription-based digital offerings [6][8] - The focus on career-oriented programs is increasing, particularly in high-demand fields like healthcare, aligning with workforce needs and supporting enrollment growth [9][10] Government Support - Federal and state initiatives are promoting EdTech adoption and workforce development, enhancing the prospects for education companies [11] - New interagency agreements aim to streamline program delivery and reduce administrative burdens, while a national policy established in April 2025 focuses on advancing AI education [11][12] Stock Performance - Chegg (CHGG) has a Zacks Rank of 1, with a projected earnings growth of 228.6% for 2026 despite a year-to-date drop of 42.9% [16] - Adtalem (ATGE) holds a Zacks Rank of 2, with a fiscal 2026 EPS estimate of $7.85 and expected growth of 17.7% [17] - Grand Canyon Education (LOPE) has a Zacks Rank of 2, with a projected earnings growth of 11.2% for 2026 [18] - Nerdy (NRDY) carries a Zacks Rank of 2, with an expected growth of 35.9% for 2026 despite a year-to-date decline of 16.7% [19] - Legacy Education (LGCY) also holds a Zacks Rank of 2, with a projected earnings growth of 11.9% for 2026 and a year-to-date gain of 23.8% [20]